2024 Rome, Italy

III-01 Clémence Rigaux
An approach for reducing the sample sizes of pediatric trials in Type 2 Diabetes Mellitus: longitudinal analysis versus standard analyses
Thursday 09:55-11:20
III-02 Matthew Riggs
M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus
Thursday 09:55-11:20
III-03 François Riglet
Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM
Thursday 09:55-11:20
III-04 Christer Rimmler
Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models
Thursday 09:55-11:20
III-05 Viktor Rognås
Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections
Thursday 09:55-11:20
III-06 Federico Romano
Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine
Thursday 09:55-11:20
III-07 Daniel Röshammar
Assessment of expected drug exposure relative maximum safety limits in early phase studies
Thursday 09:55-11:20
III-08 Ryosuke Shimizu
Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia
Thursday 09:55-11:20
III-10 Tomohisa Saito
The evaluation of a population pharmacokinetic model of Tofogliflozin with the data from healthy volunteers and T2DM patients
Thursday 09:55-11:20
III-11 Louis Sandra
A population pharmacokinetic model for propofol in (pre)term neonates and infants independently accounting for size, gestational age (GA) and postnatal age (PNA).
Thursday 09:55-11:20
III-12 Marina Savelieva
Modeling decline in cognition to decline in function in Alzheimer’s disease
Thursday 09:55-11:20
III-13 Annika Schneider
A PBPK approach for simulating the effect of liver cirrhosis on drug PK
Thursday 09:55-11:20
III-14 Rik Schoemaker
Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr
Thursday 09:55-11:20
III-15 Jérémy Seurat
Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage
Thursday 09:55-11:20
III-16 Dmitry Shchelokov
Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies
Thursday 09:55-11:20
III-17 Soyoung Shin
Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption
Thursday 09:55-11:20
III-18 Christian Siebel
Development of an adaptive dosing approach for doxorubicin in paediatric cancer patients
Thursday 09:55-11:20
III-19 Iryna Sihinevich
Mathematical Modeling of Glucose Homeostasis in Morbidly Obese Diabetic Patients Undergoing Roux-en-Y Gastric Bypass Surgery: An IMI DIRECT Study
Thursday 09:55-11:20
III-20 Florian Simon
A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics
Thursday 09:55-11:20
III-21 Noppaket Singkham
Pharmacogenetics-Based Population Pharmacokinetic Analysis for Dosing Optimization of Ritonavir-Boosted Atazanavir in Thai adult HIV-Infected Patients
Thursday 09:55-11:20
III-22 Jaydeep Sinha
Extension of the Janmahasatian fat-free mass model to account for ethnicity-related bias
Thursday 09:55-11:20
III-23 Erik Sjögren
A PBPK Framework to Predict Drug Exposure in Malnourished Children
Thursday 09:55-11:20
III-24 Eunjung Song
Selection of optimal study design based on the bioequivalence simulation study in highly variable drugs
Thursday 09:55-11:20
III-25 Elena Soto
Population Pharmacokinetic (PopPK) Modelling and Simulation of Pregabalin to Support Dose Recommendation in Paediatric Patients 1 month to <4 years of Age with Partial Onset Seizures (POS)
Thursday 09:55-11:20
III-26 Tomás Sou
Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin
Thursday 09:55-11:20
III-27 Viktoria Stachanow
Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency?
Thursday 09:55-11:20
III-28 Felix Stader
Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly
Thursday 09:55-11:20
III-29 Gabriel Stillemans
Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients
Thursday 09:55-11:20
III-30 Mark Stroh
Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology
Thursday 09:55-11:20
III-31 Herbert Struemper
Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus
Thursday 09:55-11:20
III-32 Sabine Stuebler
Systems biology model of the mucosal immune system
Thursday 09:55-11:20
III-33 Suein Choi
contribution of trough concentration data for the evaluation of multiple-dose pharmacokinetics
Thursday 09:55-11:20
III-34 Jesper Sundell
Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV
Thursday 09:55-11:20
III-35 Budi Octasari Susanto
Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development
Thursday 09:55-11:20
III-36 Hadi Taghvafard
Modeling (a)symmetry of concentration-effect curves
Thursday 09:55-11:20
III-37 Hiroyuki Takita
The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell
Thursday 09:55-11:20
III-38 Lénaïg Tanneau
Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients
Thursday 09:55-11:20
III-39 Joel Tarning
Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria
Thursday 09:55-11:20
III-40 David Ternant
Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation
Thursday 09:55-11:20
III-41 Mita Thapar
Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients.
Thursday 09:55-11:20
III-42 Anders Thorsted
Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies
Thursday 09:55-11:20
III-43 Tjokosela Tikiso
A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications.
Thursday 09:55-11:20
III-44 Pauline Traynard
New library of double absorptions PK models for the MonolixSuite, application to veralipride pharmacokinetics
Thursday 09:55-11:20
III-45 Carlos Traynor
Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival.
Thursday 09:55-11:20
III-46 Iñaki F. Trocóniz
A modelling platform for onco-immunological drugs in early drug development
Thursday 09:55-11:20
III-47 Denise Feick
Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim
Thursday 09:55-11:20
III-48 Sami Ullah
Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function
Thursday 09:55-11:20
III-49 Parth Upadhyay
Exploring the Relationship Between Midazolam Concentrations And Level Of Sedation In Critically-Ill Mechanically Ventilated Children Using Markov Modelling
Thursday 09:55-11:20
III-50 David Uster
Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A
Thursday 09:55-11:20
III-51 Pavan Vaddady
Application of Bayesian Methodology to Inform Imipenem/Relebactam Pediatric Study Design
Thursday 09:55-11:20
III-52 Cristina Vaghi
Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor
Thursday 09:55-11:20
III-53 Stijn van Beek
Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Thursday 09:55-11:20
III-54 Arthur Van De Vyver
in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics.
Thursday 09:55-11:20
III-55 Louvina van der Laan
Pharmacokinetics and drug-drug interactions of lamivudine and abacavir administered with antituberculosis drugs in HIV-infected children with multidrug-resistant tuberculosis
Thursday 09:55-11:20
III-56 Jan-Stefan van der Walt
A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics
Thursday 09:55-11:20
III-57 Tamara van Donge
Methadone dosing strategies in preterm neonates can be simplified
Thursday 09:55-11:20
III-58 Rob van Wijk
Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae
Thursday 09:55-11:20
III-59 Filippo Venezia
Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib)
Thursday 09:55-11:20
III-60 Diego Vera
Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein
Thursday 09:55-11:20
III-61 Luka Verrest
Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients
Thursday 09:55-11:20
III-62 Ludwig Vincent
How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors
Thursday 09:55-11:20
III-63 Janet Wade
Population PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR
Thursday 09:55-11:20
III-64 Ulrika Wählby Hamrén
Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling
Thursday 09:55-11:20
III-65 Wenyi Wang
Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes
Thursday 09:55-11:20
III-66 Shijun Wang
Comparison of approaches for estimating covariate effects in full random effects models
Thursday 09:55-11:20
III-67 Zhigang Wang
A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo
Thursday 09:55-11:20
III-68 Linda Wanika
Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases
Thursday 09:55-11:20
III-69 Shayne Watson
Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies
Thursday 09:55-11:20
III-70 Sebastian Weber
Qualifying drug dosing regimens in pediatrics using Gaussian Processes
Thursday 09:55-11:20
III-71 Ferdinand Weinelt
A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients
Thursday 09:55-11:20
III-72 Gustaf Wellhagen
Modelling UACR as a clinical endpoint
Thursday 09:55-11:20
III-73 Quirin Werthner
Network-based mathematical modelling of HPV transmission and cervical cancer in Germany.
Thursday 09:55-11:20
III-74 Sebastian Wicha
TDMxR: an open-source package for model-based therapeutic drug monitoring in R
Thursday 09:55-11:20
III-75 Mélanie Wilbaux
Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data
Thursday 09:55-11:20
III-76 Justin Wilkins
Population Pharmacokinetics analysis of M5717, a novel antimalarial agent
Thursday 09:55-11:20
III-77 Francis Williams Ojara
Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
Thursday 09:55-11:20
III-78 Jan-Georg Wojtyniak
Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6
Thursday 09:55-11:20
III-79 Dan Wright
Kinetic-pharmacodynamic models in the setting of non-linear drug elimination
Thursday 09:55-11:20
III-80 Xia Li
A Physiologically-Based Pharmacokinetic Model of Voriconazole
Thursday 09:55-11:20
III-81 Rujia Xie
Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections
Thursday 09:55-11:20
III-82 Estelle Yau
A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models
Thursday 09:55-11:20
III-83 Anyue Yin
Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing
Thursday 09:55-11:20
III-84 Jinqiu Yin
Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections
Thursday 09:55-11:20
III-85 Sirin Yonucu
Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach
Thursday 09:55-11:20
III-86 Jurij Aguiar Zdovc
Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors
Thursday 09:55-11:20
III-87 Yang Zhang
Ways to improve the efficiency of pharmacometric model implemented in R using deSovle – an example with a PK model for ADC
Thursday 09:55-11:20
III-88 Chenyan Zhao
Colistin to overcome resistance to ciprofloxacin - Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model
Thursday 09:55-11:20
III-89 Xuan Zhou
Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds
Thursday 09:55-11:20
III-90 Tom Zwart
Population pharmacokinetics and limited sampling of iohexol as a renal function marker
Thursday 09:55-11:20